Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2022 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management discusses their products, FDA submissions, partnerships, acquisitions, and go-to-market strategy. They mention partnerships with Evolve Manufacturing, LIVMOR acquisition, and potential customers. However, the question is about counterparties that the company already supplies or serves, and whose growth drives the company's forward story. In the transcript, management talks about their own product development, FDA clearances, and go-to-market strategy. They mention "potential customers and partners" but not specific counterparties already scaling. They talk about direct pay market segments, but not about specific customers' ramps. They mention the LIVMOR acquisition, but that's an acquisition, not a customer. They mention Evolve Manufacturing as a contract manufacturer, but that's a supplier, not a customer. The forward account is about their own milestones: FDA submissions, clearances, product launches. They do not narrate the growth of specific customers or partners that they already serve. They talk about "engaging with potential customers and partners" but that's not current activity. So the answer is NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.